Biological therapy in acute severe ulcerative colitis: Indian experience.
Biologicals have a well established role as rescue therapy in management of steroid refractory cases of Ulcerative colitis and Crohn's disease. However, high cost and potential risk of infections like tuberculosis limits their use in developing countries. As there is paucity of data on the use of various biological agents from developing countries like India, we are reporting the limited Indian experience with the available agents. Infliximab has been used as a rescue therapy for severe refractory Ulcerative colitis while other agents have been used as a part of multicentre clinical trials.
Ajit
A
Sood
Vandana
V
Midha
Arshdeep
A
Singh
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000077552:Basiliximab; D001691:Biological Therapy / Q000379:methods*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007194:India; D000069285:Infliximab; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D011993:Recombinant Fusion Proteins; C529000:golimumab; D000077552:Basiliximab; C543529:vedolizumab; D000069285:Infliximab